Ensysce Biosciences, Inc. (ENSC)

US — Healthcare Sector
Peers: ZURA  PHIO  SONN  ATNF  CDIO  VRAX  BWV  REVB  HILS  KPRX  QNRX  ALLR  KRBP  BDRX  PXMD 

Automate Your Wheel Strategy on ENSC

With Tiblio's Option Bot, you can configure your own wheel strategy including ENSC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ENSC
  • Rev/Share 2.0021
  • Book/Share 3.1986
  • PB 1.0569
  • Debt/Equity 0.0844
  • CurrentRatio 2.4989
  • ROIC -2.2055

 

  • MktCap 5452610.0
  • FreeCF/Share -4.1407
  • PFCF -0.9398
  • PE -0.4728
  • Debt/Assets 0.0558
  • DivYield 0
  • ROE -1.762

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Ensysce Biosciences Bolsters Management Team with Regulatory Expert
ENSC
Published: May 12, 2025 by: Accesswire
Sentiment: Neutral

~ Advanced Preparation for New Drug Application ~ SAN DIEGO, CA / ACCESS Newswire / May 12, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for abuse and overdose, today announced it has added Tracy Hysong, CCRA as Senior Director of Regulatory Affairs to its management team. Ms. Hysong is a Certified Clinical Research Associate (CCRA) through the Association of Clinical Research Professionals with years of experience undertaking regulatory activity at the University of California Davis (UC Davis).

Read More
image for news Ensysce Biosciences Bolsters Management Team with Regulatory Expert
Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids
ENSC
Published: March 03, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , March 3, 2025 /PRNewswire/ -- Today's Marketplace (TMP) is proud to announce a featured interview with Ensysce Biosciences (NASDAQ: ENSC) CEO Dr. Lynn Kirkpatrick and Dr. Neel Pathak, DS , Program Director with Creighton University . The doctors joined TMP's host Jane King to discuss the ongoing issues with opioids for pain management and how "clever chemistry" is being used to introduce safer opioids that are less prone to accidental overdose and abuse.

Read More
image for news Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

About Ensysce Biosciences, Inc. (ENSC)

  • IPO Date 2018-03-14
  • Website https://www.ensysce.com
  • Industry Biotechnology
  • CEO Dr. D. Lynn Kirkpatrick Ph.D.
  • Employees 7

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.